Aligos Therapeutics Inc (ALGS) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

ALGS ranks #7395 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

31 institutions disclose a position in ALGS, but none treat it as a major bet — even Sio Capital Management, LLC, its most concentrated holder, allocates just 0.3% of its own portfolio to it.

UBS Group AG has added to its ALGS position for two straight quarters, increasing it by $342.7K to reach $346.1K today.

Woodline Partners LP has trimmed its ALGS position for two straight quarters, cutting it by $1.7M while still holding $1.0M.

ALGS reported a net loss of $76.0M over the trailing twelve months.

• Not yet profitable — net loss of $76.0M over the trailing twelve months
• Revenue grew 19.4% year over year
• Net income declined year over year, from -$74.2M to -$76.0M
• Operating cash flow was negative, using $82.5M in cash
• Current ratio of 3.90x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.65x equity — within a conventional range